US Patent Office Creates Accelerated Path For COVID-19 Products
The US Patent and Trademark Office has launched a prioritized pathway for small entities creating FDA-regulated products to treat or diagnose COVID-19.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
The data compares the sensitivity of almost 200 diagnostics against a standardized set of samples.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.